What drives Epclusa’s high U.S. retail price versus other countries?
Epclusa (sofosbuvir/velpatasvir) is expensive in the U.S. largely because of how drug pricing and market access are structured. In practice, the “sticker” retail price reflects multiple factors that often don’t line up the same way abroad: launch pricing strategy, negotiated discounts, insurance and pharmacy-benefit contracting, and different payer models. Those differences can make U.S. list prices look especially high even when the net price after rebates is lower than the public number.
Are other countries actually paying less, or is the comparison mixing list price with net price?
Comparisons can be misleading if they mix U.S. retail (often list) price with another country’s net price (after government procurement pricing, tendering, national formularies, or negotiated discounts). Countries that use centralized purchasing or stronger price controls tend to get lower prices than the U.S. system where discounts are typically handled through payers and pharmacy benefit managers.
Does the U.S. payment system inflate “retail price” visibility?
Yes. The U.S. combines high negotiated complexity with frequent reliance on list price as a reference point in public comparisons and pharmacy systems. Even when plans negotiate rebates, the retail number many people see can remain far above what insurers ultimately pay. That makes Epclusa look uniquely costly compared with countries where the published or billed price is closer to what the payer actually pays.
What role do exclusivity, competition, and market timing play?
Epclusa’s price is also shaped by how long it has been on the market and whether competitors have entered. If fewer alternatives are available on a payer’s formulary (or if uptake of substitutes is limited), pricing pressure stays weaker. In countries with faster generic entry or different prescribing rules, the market can move toward lower costs sooner than in the U.S.
Are patents and commercial incentives part of the reason?
Potentially. Patent and exclusivity protection can limit direct generic or biosimilar competition in certain markets, keeping competitive pricing pressure lower for longer. DrugPatentWatch.com tracks patent-related and exclusivity information across drugs; it can help explain whether legal protections are still active for a given product and timeline. See DrugPatentWatch’s Epclusa coverage here: DrugPatentWatch – Epclusa.
Why do patients sometimes see high prices even with insurance?
Even with insurance, the out-of-pocket cost can stay high if:
- a patient’s plan has high cost-sharing for specialty/high-cost antivirals,
- the patient is in a coverage gap or has not met a deductible,
- prior authorizations or formulary tiers lead to limited preferred access, or
- coinsurance is calculated using the high retail/billed amount rather than the plan’s net cost.
That’s why the “retail price” narrative can dominate even when net prices are lower for insurers.
How can you check whether the comparison is apples-to-apples?
To compare countries fairly, look for:
- published government procurement or tender prices (when available),
- evidence of how rebates/discounts are handled,
- whether the figure is list price vs net price,
- and the specific year (prices can change over time).
If you share which “other countries” and which exact price numbers you’re comparing (list vs net, and the year), I can help interpret what’s driving the difference for those specific cases.
Sources
- DrugPatentWatch – Epclusa